



Syncrom Formulations (India) Limited

A WHO-GMP & ISO 9001-2000 Certified Company

CIN No.: L24239MH1988PLC047759

SYNCOM/SE/2025-26

12th February, 2026

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated Unaudited Financial Results along with Limited Review Report, for the quarter and Nine months ended on 31st December, 2025.

Dear Sir/Ma'am

This is in continuation of our letter no. **SYNCOM/SE/2025-26** dated 04th February, 2026 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated UnAudited Financial Results for the Quarter and Nine months ended 31st December, 2025.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2025;
2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter and Nine months ended 31st December, 2025;

which was considered and approved by the Board at their Meeting held on Thursday, the 12th February, 2026 at 3:00 P.M. and **Concluded at 4:30 P.M.**

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

The Board Meeting commenced at 3:00 P.M. and **Concluded at 4:30 P.M.**

You are requested to take on record the unaudited Financial Results along with Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,
For, SYNCOM FORMULATIONS (INDIA) LIMITED

**CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER**

Encl: a/a

Bringing a smile on every face...

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), **MUMBAI-400 093, INDIA**, Tel.: 91-022-30887744-54, Fax: 91-022-30887755, Email: sfil87@syncomformulations.com

Works : 256-257, Sector-I, **PITHAMPUR**, Dist.-Dhar, M.P. - 454 775, **INDIA**, Tel.: 91-07292-403122, 407039, Fax: 91-07292-253404, Email: assistant2@sfil.in

Corp. Off. : 207, Saket Nagar, Near Saket Club, **INDORE - 452 018, INDIA**. Tel. : 91-0731-2700458, Email : finance@sfil.in

Website : <http://www.sfil.in>

Limited Review Report on Un-audited Standalone Financial Results for the Quarter ended 31st December, 2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Company"), for the period ended December, 31, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C


CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 26079452EGPPEM5738



Place: Indore
Date: 12-02-2026



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 258-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfli.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047758

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER , 2025

S. No.	Particulars	Quarter Ended			Year to date Ended	(Rs.In Lakhs) (Except EPS)
		31/12/2025	30/09/2025	31/12/2024		
		Unaudited	Unaudited	Unaudited	31/12/2025	31/03/2025
1	Revenue from Operations	11459.05	12143.51	12702.92	35257.25	31438.60
2	Other Income	548.39	523.44	382.49	1673.80	1028.81
3	Total Income (1 + 2)	12007.44	12666.95	13085.41	36931.05	32467.41
4	EXPENSES					48004.05
	(a) Cost of materials consumed	4744.91	4642.83	7626.18	15348.84	19786.88
	(b) Purchases of Stock-in-Trade	1557.44	1535.33	712.91	4654.70	2379.23
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(217.97)	909.36	323.08	75.00	(1501.04)
	(d) Employee benefits expense	1745.26	1673.08	1394.75	5013.78	(1062.24)
	(e) Finance costs	25.00	25.03	21.23	73.77	3719.90
	(f) Depreciation and amortization expense	136.00	135.00	130.75	405.00	85.02
	(g) Other expenses	1511.98	1510.77	1186.03	4597.69	3450.30
	Total expenses (4)	9502.62	10431.20	11394.93	30168.78	28302.12
5	Profit/(loss) before exceptional items and tax (3-4)	2504.82	2235.75	1690.48	6762.27	41538.81
6	Exceptional Items	0.00	0.00	0.00	4.13	6465.24
7	Profit/(loss) before tax (5 - 6)	2504.82	2235.75	1690.48	6765.40	4153.58
8	Tax expense:					6465.82
	(1) Current tax	600.12	522.00	402.82	1553.72	995.14
	(2) Deferred tax	18.36	29.64	8.54	69.30	32.93
9	Profit (Loss) for the period from continuing operations (7-8)	1886.34	1684.11	1279.12	5143.38	3136.98
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	4887.18
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	1886.34	1684.11	1279.12	5143.38	3136.98
14	Other Comprehensive Income					4887.18
	A(i)Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	235.18	(5.58)	18.40	634.44	686.21
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	458.02
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	2122.52	1678.53	1297.52	5777.82	3823.19
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	5345.20
17	Reserves excluding revaluation reserves	-	-	-	-	9400.00
18	Earnings per equity share (for continuing operation):					24590.38
	(1) Basic	0.23	0.18	0.14	0.61	0.41
	(2) Diluted	0.23	0.18	0.14	0.61	0.41
19	Earnings per equity share (for discontinued operation):					0.57
	(1) Basic	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)					0.57
	(1) Basic	0.23	0.18	0.14	0.61	0.41
	(2) Diluted	0.23	0.18	0.14	0.61	0.41

Place: Indore

Date: 12/02/2026

For, Syncom Formulations (India) Limited

Arunit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfli.in, Website:- www.sfil.in, CIN:- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND NINE MONTHS ENDED UNAUDITED RESULTS


S. No.	Particulars	Quarter Ended		Year to date Ended		Previous Year Ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	
		Unaudited	Unaudited	Unaudited	Unaudited	
1	Segment Revenue					
	a) Pharmaceuticals Drugs & Formulations	11917.80	12567.59	12766.27	36548.01	31570.03
	b) Trading of Commodities	1.44	0.00	226.88	106.00	612.39
	c) Renting of Property	86.20	99.26	90.28	277.04	284.99
	Total Segment Revenue	12007.44	12666.85	13085.41	36931.05	32467.41
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
	Revenue from Operations	12007.44	12666.85	13085.41	36931.05	32467.41
2	Segment Results Profit(+) / Loss(-) before tax and interest from each segment					
	a) Pharmaceuticals Drugs & Formulations	2447.26	2167.52	1626.16	6579.43	3964.21
	b) Trading of Commodities	0.37	0.00	3.37	1.72	16.16
	c) Renting of Property	82.19	93.26	82.18	259.02	280.78
	Total Profit before tax	2529.82	2260.78	1711.71	6840.17	4241.15
	Less: i) Interest	25.00	25.03	21.23	73.77	76.10
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00
	Profit before tax	2504.82	2235.75	1690.48	6766.40	4165.05
3	(Segment Asset-Segment Liabilities)					
	Segment Asset					
	a) Pharmaceuticals Drugs & Formulations	45198.48	40128.78	32536.81	45198.48	32536.81
	b) Trading of Commodities	179.35	251.35	890.60	179.35	890.60
	c) Renting of Property	3853.87	4733.44	4733.45	3853.87	4733.45
	Total Segment Asset	49231.70	45113.57	38160.86	49231.70	38160.86
	Un-allocable Assets	0.00	0.00	0.00	0.00	0.00
	Net Segment Asset	49231.70	45113.57	38160.86	49231.70	38160.86
	Segment Liabilities					
	a) Pharmaceuticals Drugs & Formulations	9371.45	7332.38	5460.01	9371.45	5460.01
	b) Trading of Commodities	0.00	2.11	155.00	0.00	155.00
	c) Renting of Property	92.05	133.40	77.48	92.05	77.48
	Total Segment Liabilities	9463.50	7467.89	5692.49	9463.50	5692.49
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	9463.50	7467.89	5692.49	9463.50	5692.49

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/02/2026.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter and nine months ended on 31st December 2025. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The Government of India has notified four Labour Codes - namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 - with effect from 21 November 2025, which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes, but the relevant rules are yet to be notified. Based on the available information as at reporting date, no material liability is envisaged in this regard. Financial impact will be reviewed once the relevant rules are notified.
- The Company has received an intimation regarding rejection of appeal and demand of ₹70,89,302 towards ineligible Input Tax Credit along with equivalent penalty under Sections 74(5) and 122 of the CGST Act, 2017 (total ₹1,41,78,604). The Company is obtaining legal advice and proposes to contest the matter by filing an appeal before the appropriate appellate authority.

Place: Indore

Date: 12/02/2026



**Limited Review Report on Un-audited Consolidated Financial Results for the Quarter
ended 31st December, 2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015**

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended December 31, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entity:

S. No.	Name of the Company	Relationship with the Holding Company
1.	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary



5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C



CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 26079452SWVJTE2257



Place: Indore
Date: 12-02-2026



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfli.in; Website:- www.sflin.in; CIN - L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2025

S. No.	Particulars	Quarter Ended			Year to date ended		Rs. In Lacs except EPS
		31/12/2025 Unaudited	30/09/2025 Unaudited	31/12/2024 Unaudited	31/12/2025 Unaudited	31/12/2024 Unaudited	31/03/2025 *Audited
1	Revenue from Operations						
2	Other Income	11514.06	12171.74	12753.32	35375.97	31813.62	46501.26
3	Total Income (1 + 2)	550.09	525.05	403.70	1678.61	1049.12	1743.40
4	EXPENSES						
	(a) Cost of materials consumed	4744.91	4642.63	7626.18	15348.84	19786.88	27802.83
	(b) Purchases of Stock-in-Trade	1571.08	1529.13	722.52	4668.34	2417.47	3996.75
	(c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(212.32)	903.71	316.76	78.91	(1507.36)	(1066.15)
	(d) Employee benefits expense	1745.26	1673.08	1394.75	5013.78	3719.90	5217.37
	(e) Finance costs	26.34	26.49	19.82	77.91	74.81	86.49
	(f) Depreciation and amortization expense	136.00	135.00	130.75	405.00	390.75	519.39
	(g) Other expenses	1544.08	1583.10	1219.92	4724.24	3558.79	5137.19
	Total expenses (4)	9555.35	10493.14	11430.80	30317.02	28441.24	41693.97
5	Profit/(loss) before exceptional items and tax (3-4)	2508.80	2203.55	1726.22	6737.56	4221.50	6550.69
6	Exceptional Items	0.00	0.00	0.00	4.13	(0.24)	0.53
7	Profit/(loss) before tax (5 - 6)	2508.80	2203.65	1726.22	6741.69	4221.26	6551.27
8	Tax expense:						
	(1) Current tax	599.63	513.80	417.61	1546.03	1014.43	1474.43
	(2) Deferred tax	18.36	29.64	8.41	69.30	32.80	133.38
9	Profit (Loss) for the period from continuing operations (7-8)	1890.81	1660.11	1300.20	5126.36	3174.03	4943.46
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	1890.81	1660.11	1300.20	5126.36	3174.03	4943.46
14	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	236.18	(5.58)	18.40	634.44	686.21	458.02
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	2126.89	1654.63	1318.60	5760.80	3860.24	5401.48
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	8400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	-	-	-	-	-	24815.76
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.23	0.18	0.14	0.61	0.41	0.57
19	(2) Diluted	0.23	0.18	0.14	0.61	0.41	0.57
20	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings per equity share (for discontinued & continuing operations)	0.23	0.18	0.14	0.51	0.41	0.57
	(1) Basic	0.23	0.18	0.14	0.61	0.41	0.57
	(2) Diluted	0.23	0.18	0.14	0.61	0.41	0.57

Place: Indore

Date: 12/02/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND NINE MONTHS ENDED 31ST DECEMBER, 2025 UNAUDITED RESULTS

S. No.	Particulars	Quarter Ended			Year to date ended		Year Ended
		31/12/2025 Unaudited	30/09/2025 Unaudited	31/12/2024 Unaudited	31/12/2025 Unaudited	31/12/2024 Unaudited	31/03/2025 Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	11,974.96	12,597.88	12839.41	35672.89	31767.79	47,027.33
	b) Trading of Commodities	1.44	0.00	228.88	106.00	812.39	825.84
	c) Renting of Property	87.75	98.81	86.73	275.69	282.56	381.49
	Total Segment Revenue	12,064.15	12,696.79	13157.02	37,054.58	32,662.74	48,244.66
	Less: Inter Segment Revenue:	0.00	0.00	0.00	0.00	0.00	0.00
	Revenue from Operations	12,064.15	12,696.79	13157.02	37,054.58	32,662.74	48,244.66
2	Segment Results Profit(+) / Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	2,459.03	2,131.33	1662.02	6560.21	4021.56	6,258.62
	b) Trading of Commodities	0.37	0.00	3.37	1.72	16.16	20.35
	c) Renting of Property	75.74	98.81	80.65	257.67	258.35	358.79
	Total Profit before tax	2,535.14	2,230.14	1746.04	6,819.60	4,296.07	6,637.76
	Less: i) Interest	26.34	26.49	19.82	77.91	74.81	86.49
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit before tax:	2,508.80	2,203.65	1726.22	6,741.69	4,221.26	6,551.27
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	45,481.37	40,623.55	32946.55	45481.37	32946.55	36,111.42
	b) Trading of Commodities	178.80	251.35	890.60	178.80	890.60	448.67
	c) Renting of Property	3,853.87	4,733.44	4733.45	3853.87	4733.45	4,767.98
	Total Segment Asset	49,514.04	45,608.34	38570.60	49,514.04	38,570.60	41,328.07
	Un-allocable Assets			0.00		0.00	-
	Net Segment Asset	49,514.04	45,608.34	38570.60	49,514.04	38,570.60	41,328.07
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	9,446.14	7,823.26	5663.84	9448.14	5663.84	6,888.49
	b) Trading of Commodities	0.00	2.11	155.00	0.00	155.00	82.75
	c) Renting of Property	91.97	133.40	77.43	91.97	77.43	141.04
	Total Segment Liabilities	9,540.11	7,758.77	5896.07	9,540.11	5,896.07	7,112.29
	Un-allocable Liabilities			0.00	0.00	0.00	0.00
	Net Segment Liabilities	9,540.11	7,758.77	5896.07	9,540.11	5,896.07	7,112.29

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/02/2026
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 31st December, 2025. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd. And Vincit Biotech International Pvt. Ltd.
- The Government of India has notified four Labour Codes - namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 - with effect from 21 November 2025, which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes, but the relevant rules are yet to be notified. Based on the available information as at reporting date, no material liability is envisaged in this regard. Financial impact will be reviewed once the relevant rules are notified.
- Syncom has received an intimation regarding rejection of appeal and demand of ₹70,89,302 towards ineligible Input Tax Credit along with equivalent penalty under Sections 74(5) and 122 of the CGST Act, 2017 (total ₹1,41,78,604). The Company is obtaining legal advice and proposes to contest the matter by filing an appeal before the appropriate appellate authority.

Place: Indore
Date: 12/02/2026



For Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461